Українська Русский English

ISSN 2522-9028 (Print)
ISSN 2522-9036 (Online)
DOI: https://doi.org/10.15407/fz

Fiziologichnyi Zhurnal

is a scientific journal issued by the

Bogomoletz Institute of Physiology
National Academy of Sciences of Ukraine

Editor-in-chief: V.F. Sagach

The journal was founded in 1955 as
1955 – 1977 "Fiziolohichnyi zhurnal" (ISSN 0015 – 3311)
1978 – 1993 "Fiziologicheskii zhurnal" (ISSN 0201 – 8489)
1994 – 2016 "Fiziolohichnyi zhurnal" (ISSN 0201 – 8489)
2017 – "Fiziolohichnyi zhurnal" (ISSN 2522-9028)

Fiziol. Zh. 2009; 55(3): 75-80


Modelling of insulin resistance and accompanyingmetabolic disturbances with dexametazone

L.L.vavilova, T.A.krjachok, T.V.talaievA.

    National Scientific Center ”N.D. Strazhesko InstituteCardiology”, Ukrainian Academy of Medical Sciences,Kyiv


Abstract

In experiment carried out on 12 rabbits, the possibility of reproduction of insulin resistance syndrome components in the absence of obesity as initiating factor was assessed. The ex­perimental rabbits were subjected to subcutaneous injections of synthetic glucocorticoid dexametazone during 8 weeks in the dose 15 mkg/kg. The obtained data showed a progressive de­cline in insulin sensitivity in the course of the experiment, and at the end of the 8-th week the reaction to subcutaneous insulininjection decreased by 82%, the content of glycosilated hemo­globin increased by 200%. These changes were accompanied by increased Tg content in blood by 67%, the contents of total cholesterol and free fatty acids were increased by 109% and 176%, respectively. The C-reactive protein content in blood in­creased 12,5 times, indicating intensification of systemic inflammation, and the activity of angiotensin-converting enzyme increased by 215%. These changes were noted in the absence of body weight shifts indicating on the possibility of insulin resistance development as the result of primary disturbances in intracellular lipid metabolism in the absence of systemic obesity, which promotes the development of insulin resistance but does not trigger it.

References

  1. Талаєва Т.В., Ларіонов О.П., Крячок Т.В.та ін. Характер та механізми порушень обміну ліпопро-теїнів при відтворенні системного запалення в умовах експерименту // Укр. кардіол. журн. - 2006, № 4. -С.63-70.
  2. Aas V., Rokling-Andersen M.H., Kase E.T. et al. Eicosapentaenoic acid (20:5 n-3) increases fatty acid and glucose uptake in cultured human skeletal muscle cells // J. Lipid Res. - 2006. - 47. - P.366-374.
  3. Caglyan E., Blaschke F., Takata Y. et al. Metabolic syn­drome-interdependence of the cardiovascular and meta­bolic pathways // Curr.Opin.Pharmacol. - 2005. - 5. -P.135-142.
  4. Cefalu W.T. Insulin resistance and cardiometabolic risk. -In: Atlas of cardiometabolic risk / Ed.by W.T.Cefal, Ch.P. Cannon. - New-York. - London: Informa Healthcare, 2007. - P.27-37.
  5. Crandall D.L., Quinet E.M.; El Ayachi S. et al. Modu­lation of adipose tissue development by pharmacologi-cal inhibition of PAI-1 // Arterioscler. Thromb. Vascu­lar. Biol. - 2006. - 26. - P.2209-2218.
  6. Fried S.K., Bunkin D.A., Greenberg A.S. Omental and sub­cutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid // J.Clin. Endocrinol. and Metabol. - 1998. - 83. - P.847-850.
  7. Gan S.K., Krikeos A.D., Poynten A.M. et al. Insulin action, regional fat, and myocyte lipid; altered relationships with increased adiposity // Obes.Res. -2003. - 11. - P.1295-1305.
  8. Gray R.S., Fabsitz R.R., Cowan L.D. et al. Risk factor clustering in the insulin resistance syndrome. The Strong Heart Study // Amer. J.Epidemiol. - 1998. - 148. -P.869-878.
  9. 9. Halleux C.M., Declerck P.J., Tran S.L. et al. Hormonal control of plasminogen activator inhibitor-1 gene expres­sion and production in human adipose tissue: stimulation by glucocorticoids and inhibition by catecholamines // J. Clin. Endocrinol. And Metabol. - 1999. - 84. - P. 4097–4105.
  10. 10. Itoh M., Suganami T., Satoh N. et al. Increased adiponectin secretion by highly purified eicosapentaenoic acid in rodent models of obesity and human obese sub­jects // Arterioscler. Thromb. Vascular. Biol. - 2007. -27. - P.1918-1927.
  11. Korach-Andm M., Gao J., Gounarides J. S. et al. Relationship between visceral adiposity and intramyo-cellular lipid content in two rat models of insulin resistance // Amer. J.Physiol. Endocrinol. and Metabol. - 2005. -288. - P. E106-E116.
  12. Morange P.E., Aubert J., Peiretti F. et al. Glucocorti­coids and insulin promote plasminogen activator inhibi­tor 1 production by human adipose tissue // Diabetes. -1999. – 48. - P.890-895.
  13. Rahmouni K., Mark A.L., Haynes W.G., Sigmund CD. Adipose depot-specific modulation of angiotensinogen gene expression in diet-induced obesity // Amer. J. Physiol. Endocrinol. and Metabol. - 2004. - 286. -P. E891-E895.
  14. Reaven G.M. Compensatory hyperinsulinemia and the development of an atherogenic lipoprotein profile: The price paid to maintain glucose homeostasis in insulin-resistant individuals // Endocrinol.Metab.Clin.North. -Amer. - 2005. - 34. - P.49-62.
  15. Reaven G.M. The metabolic syndrome: requiescat in pace // Clin.Chem. - 2005. - 51. - P.931-938.
  16. Reaven G. All obese individuals are not created equal: insulin resistance is the major determinant of cardiovas­cular disease in overweight/obese individuals // Diabe­tes Vascular. Dis. Res. - 2005. - 2. - P.105-112.
  17. Reaven G.M. The metabolic syndrome: is this diagnosis necessary? // Amer. J.Clin. Nutr. - 2006. - 83, №6. -P.1237-1247.
  18. Shankar R.R., Wu Y, Shen H.Q. et al. Mice with gene disruption of both endothelial and neuronal nitric oxide synthase exhibit insulin resistance // Diabetes. - 2000. -49. - P.684-687.
  19. 19. Tomlinson J.W., Finney J., Hughes B.A. et al. Reduced glucocorticoid production rate, decreased 5 6-reductase activity, and adipose tissue insulin sensitization after weight loss // Ibid. - 2008. - 57. - P.1536-1543.

© National Academy of Sciences of Ukraine, Bogomoletz Institute of Physiology, 2014-2019.